



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 7, 2021

Thomas Striepe
Chief Financial Officer
SANGUI BIOTECH INTERNATIONAL INC
Bleichenbrücke 9, 20354
Hamburg, Germany

Re: SANGUI BIOTECH INTERNATIONAL INC
Form 10-K for the Fiscal Year Ended June 30, 2020
Filed September 30, 2020
File No: 000-29233

Dear Mr. Striepe:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences